<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CORTIFOAM- hydrocortisone acetate aerosol, foam </strong><br>Schwarz Pharma<br></p></div>
<h1>CORTIFOAM®<br>(HYDROCORTISONE ACETATE RECTAL AEROSOL)<br>10% RECTAL FOAM</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_FAD4B62D-6C01-4EB4-B275-F31669454858"></a><a name="section-2"></a><p></p>
<h1>Description</h1>
<p class="First">Cortifoam® (hydrocortisone acetate rectal aerosol) 10% Rectal Foam contains hydrocortisone acetate 10% in a base containing propylene glycol, emulsifying wax, polyoxyethylene-10-stearyl ether, cetyl alcohol, methylparaben, propylparaben, trolamine, purified water and inert propellants: isobutane and propane.</p>
<p>Each application delivers approximately 900 mg of foam containing 80 mg of hydrocortisone (90 mg of hydrocortisone acetate).</p>
<p>The molecular weight of hydrocortisone acetate is 404.50. It is designated chemically as pregn-4-ene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-,(11β)-. The empirical formula is C<span class="Sub">23</span>H<span class="Sub">32</span>O<span class="Sub">6</span> and the structural formula is:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36F623DF-2AE3-4858-9783-C058097951F4&amp;name=cortifoam-03.jpg"></div>
<p>Hydrocortisone acetate, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is insoluble in water (1 mg/100 mL) and slightly soluble in alcohol and chloroform.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_780D6F5E-CC71-4FB7-8B18-B1927DA79D20"></a><a name="section-3"></a><p></p>
<h1>Clinical Pharmacology</h1>
<p class="First">Cortifoam® provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of <span class="product-label-link" type="condition" conceptid="75580" conceptname="Chronic ulcerative proctitis">ulcerative proctitis</span>. Direct observations of methylene blue-containing foam have shown staining about 10 centimeters into the rectum.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_3C707DB8-463D-428B-8920-B0A17F63CE44"></a><a name="section-4"></a><p></p>
<h1>Indications and Usage</h1>
<p class="First">Cortifoam® is indicated as adjunctive therapy in the topical treatment of <span class="product-label-link" type="condition" conceptid="75580" conceptname="Chronic ulcerative proctitis">ulcerative proctitis</span> of the distal portion of the rectum in patients who cannot retain hydrocortisone or other corticosteroid enemas.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_E04A2420-967F-4ED8-B03A-F261FFC4B5F0"></a><a name="section-5"></a><p></p>
<h1>Contraindications</h1>
<p class="First">Cortifoam® is contraindicated in patients who are hypersensitive to any components of this product.</p>
<p>Local contraindications to the use of intrarectal steroids include obstruction, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, perforation, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, fresh intestinal anastomoses, extensive <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistulas</span> and sinus tracts.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_61550C3D-3B9B-4B0E-9322-2C12295E42C7"></a><a name="section-6"></a><p></p>
<h1>Warnings</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_20244E02-19BA-4FF9-8833-8895199C3797"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Do not insert any part of the aerosol container directly into the anus. Contents of the container are under pressure. Do not burn or puncture the aerosol container. Do not store at temperatures above 120°F. Because Cortifoam® is not expelled, systemic hydrocortisone absorption may be greater from Cortifoam® than from corticosteroid enema formulations. If there is not evidence of clinical or proctologic improvement within two or three weeks after starting Cortifoam® therapy, or if the patient’s condition worsens, discontinue the drug.</p>
<p>Rare instances of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving corticosteroid therapy (see <a href="#i4i_adverse_effects_ID_CC7D5A7A-61C3-4A25-B0DB-23E85444428F">Adverse Reactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_0C13F387-97FC-4091-BB16-167313532F38"></a><a name="section-6.2"></a><p></p>
<h2>Cardio-renal</h2>
<p class="First">Corticosteroids can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p>
<p>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with great caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_116DF4EC-157E-43F0-8D72-29EC95546AAE"></a><a name="section-6.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.</p>
<p>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7C78A224-22CA-4132-AE39-CE442FFE7C50"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_6810C788-D937-4B12-B108-2904256DCDFC"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Bold"><span class="Emphasis">General</span></span></h3>
<p class="First">Patients who are on corticosteroids are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than are healthy individuals.  There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with any pathogen (viral, bacterial, fungal, protozoan or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B38499A2-DC42-4276-AC00-E03290DB4C9A"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span></span></span></h3>
<p class="First">Corticosteroids may exacerbate systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and therefore should not be used in the presence of such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> unless they are needed to control drug reactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see <a href="#i4i_section_ID_0817FD94-6348-454F-BC25-5F3086976580">Amphotericin B injection and potassium-depleting agents</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_6AFFBAC3-05AD-437E-9A98-612ADD929A7E"></a><a name="section-6.4.3"></a><p></p>
<h3><span class="Bold"><span class="Emphasis">Special pathogens</span></span></h3>
<p class="First">Latent disease may be activated or there may be an exacerbation of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to pathogens, including those caused by Amoeba, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis, and Toxoplasma.</p>
<p>It is recommended that latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Similarly, corticosteroids should be used with great care in patients with known or suspected <span class="Italics">Strongyloides</span> (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to <span class="Italics">Strongyloides</span> hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_173D42E3-F924-4429-845C-C74C5929280F"></a><a name="section-6.4.4"></a><p></p>
<h3><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></span></span></h3>
<p class="First">If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7572F4D2-7F2D-43B7-BABA-EE74F64FC6AB"></a><a name="section-6.4.5"></a><p></p>
<h3><span class="Bold"><span class="Emphasis">Vaccination</span></span></h3>
<p class="First"><span class="Bold"><span class="Emphasis">Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids.  Killed or inactivated vaccines may be administered.  However, the response to such vaccines cannot be predicted. </span></span>Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_9FE4D5D4-F298-440A-8B7F-B78E1DB5EC4F"></a><a name="section-6.4.6"></a><p></p>
<h3><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span></span></span></h3>
<p class="First">Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure.  The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with immunoglobulin (IG) may be indicated.  (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_51CF0983-7479-4E35-8FE0-E75BA745D5CE"></a><a name="section-6.4.7"></a><p></p>
<h3><span class="Bold"><span class="Emphasis">Ophthalmic</span></span></h3>
<p class="First">Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi, or viruses. The use of oral corticosteroids is not recommended in the treatment of <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_09E6E7BA-B4FF-4365-941A-17EA33C72FA7"></a><a name="section-7"></a><p></p>
<h1>
<span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span> </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_5C4C8501-A508-429A-84DA-D81038840B41"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The lowest possible dose of corticosteroid should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual.</p>
<p>Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</p>
<p>Kaposi’s <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E3C8E1CE-ECD3-4A7F-BBFF-4CB855716363"></a><a name="section-7.2"></a><p></p>
<h2>Cardio-renal</h2>
<p class="First">As <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with resultant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_0ABEAA31-C77B-4E3A-A42C-352C2B510CC1"></a><a name="section-7.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_672C83D4-1272-415D-847F-08BA779D88B9"></a><a name="section-7.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Steroids should be used with caution in active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, and nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, since they may increase the risk of a perforation.  Where surgery is imminent, it is hazardous to wait more than a few days for a satisfactory response to medical treatment.</p>
<p>Do not employ in immediate or early postoperative period following ileorectostomy.</p>
<p>Signs of peritoneal irritation following <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients receiving corticosteroids may be minimal or absent.</p>
<p>There is an enhanced effect of corticosteroids in patients with cirrhosis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_779ABF3A-3713-42EC-8D33-C3F6F402C858"></a><a name="section-7.5"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First">Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age.  Special consideration should be given to patients at increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (i.e., postmenopausal women) before initiating corticosteroid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B0EEED0E-D879-4ED4-A9EC-0007E55AD5CC"></a><a name="section-7.6"></a><p></p>
<h2>Neuro-psychiatric</h2>
<p class="First">An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium).  This <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> is generalized, may involve ocular and respiratory muscles, and may result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations.  Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_A29D3287-B46B-464C-AC8A-3B463D74BE3C"></a><a name="section-7.7"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First">Intraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_411CC595-F91B-44AF-9FD6-8DB1BBDB7D95"></a><a name="section-7.8"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids and to seek medical advice at once should they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Persons who are on corticosteroids should be warned to avoid exposure to chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_31A9D171-6879-44DB-9956-9D156BA1A287"></a><a name="section-7.9"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_33D69282-A9DE-4264-9EF5-B4F230AFD235"></a><a name="section-7.9.1"></a><p></p>
<h3>Aminoglutethimide</h3>
<p class="First">Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_0817FD94-6348-454F-BC25-5F3086976580"></a><a name="section-7.9.2"></a><p></p>
<h3>Amphotericin B injection and potassium-depleting agents</h3>
<p class="First">When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.  There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B76042BD-9418-4275-81C8-ED692FE10382"></a><a name="section-7.9.3"></a><p></p>
<h3>Antibiotics</h3>
<p class="First">Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_942DE237-054C-458E-8A5C-ABD68BAF933B"></a><a name="section-7.9.4"></a><p></p>
<h3>Anticholinesterases</h3>
<p class="First">Concomitant use of anticholinesterase agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_5C18FB38-4EF1-4222-AF9D-9CC9F542AA72"></a><a name="section-7.9.5"></a><p></p>
<h3>Anticoagulants, oral</h3>
<p class="First">Coadministration of corticosteroids and warfarin result in inhibition of response to warfarin. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B6AEBE0E-B808-45AF-AB09-EDCB6BBAFDBC"></a><a name="section-7.9.6"></a><p></p>
<h3>Antidiabetics</h3>
<p class="First">Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_46ACD6E0-34BA-4EC8-AC6A-8FC7408135D2"></a><a name="section-7.9.7"></a><p></p>
<h3>Antitubercular drugs</h3>
<p class="First">Serum concentrations of isoniazid may be decreased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7E617595-C096-414A-AB46-F8EF11712F82"></a><a name="section-7.9.8"></a><p></p>
<h3>Cholestyramine</h3>
<p class="First">Cholestyramine may increase the clearance of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_40572F56-F3F8-4EEE-BA57-C4F943A685B0"></a><a name="section-7.9.9"></a><p></p>
<h3>Cyclosporine</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporine and corticosteroids may occur when the two are used concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with this concurrent use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_82EC161A-833C-4F2C-A066-807EC29205DD"></a><a name="section-7.9.10"></a><p></p>
<h3>Digitalis glycosides</h3>
<p class="First">Patients on digitalis glycosides may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_A73B7855-172A-4459-8BAA-2C84C28F670B"></a><a name="section-7.9.11"></a><p></p>
<h3>Estrogens, including oral contraceptives</h3>
<p class="First">Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_93D66831-28C1-46CF-8F0B-E6FC71703CE9"></a><a name="section-7.9.12"></a><p></p>
<h3>Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin)</h3>
<p class="First">Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_940137A0-FECA-4B2E-AC98-4FC8E327A605"></a><a name="section-7.9.13"></a><p></p>
<h3>Ketoconazole</h3>
<p class="First">Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_2C521944-08D1-4C91-8A2D-FDE602BE6607"></a><a name="section-7.9.14"></a><p></p>
<h3>Nonsteroidal anti-inflammatory agents (NSAIDS)</h3>
<p class="First">Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.  The clearance of salicylates may be increased with concurrent use of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_28A5DEB8-FDE6-4ADC-B52E-85C925F8C6BE"></a><a name="section-7.9.15"></a><p></p>
<h3>Skin tests</h3>
<p class="First">Corticosteroids may suppress reactions to skin tests.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_90D8837C-74DF-4D37-A327-1DC6937AE103"></a><a name="section-7.9.16"></a><p></p>
<h3>Vaccines</h3>
<p class="First">Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids  may also potentiate the replication of some organisms contained in live attenuated vaccines.  Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see <a href="#i4i_section_ID_7572F4D2-7F2D-43B7-BABA-EE74F64FC6AB">Vaccination</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_84C32DE9-8654-423A-8D69-7603C2FFC145"></a><a name="section-7.10"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis.</p>
<p>Steroids may increase or decrease motility and number of spermatozoa in some patients.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_DF5832DD-365F-4121-A357-5E0B2F73D70E"></a><a name="section-7.11"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_ID_C7B943FE-3FBA-409A-BCF8-7AF26C6A88E7"></a><a name="section-7.11.1"></a><p></p>
<h3>Teratogenic effects: Pregnancy Category C</h3>
<p class="First">Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in the offspring.  There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_DFEC3D5E-B4AC-4E52-95A8-228A6283AC24"></a><a name="section-7.12"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.  Caution should be exercised when corticosteroids are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_153D9FE6-FA6B-47C4-8605-5718ED3F068B"></a><a name="section-7.13"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_25CDD8C3-7587-49CD-94BF-01FE142A7AFB"></a><a name="section-7.14"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_CC7D5A7A-61C3-4A25-B0DB-23E85444428F"></a><a name="section-8"></a><p></p>
<h1>Adverse Reactions</h1>
<p class="First"><span class="Bold"><span class="Emphasis">(listed alphabetically, under each subsection)</span></span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span></span>: <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Italics">Cardiovascular</span>: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, cardiac enlargement, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> in premature infants, <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (see<a href="#i4i_warnings_ID_61550C3D-3B9B-4B0E-9322-2C12295E42C7">Warnings</a>S), <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Italics">Dermatologic</span>: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, cutaneous and subcutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, dry scaly skin, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyperpigmentation, hypopigmentation, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Endocrine</span>: Decreased carbohydrate and glucose tolerance, development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, increased requirements for insulin or oral hypoglycemic agents in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness), suppression of growth in pediatric patients.</p>
<p><span class="Italics">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span></span>: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>, potassium loss, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>.</p>
<p>Where <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and other symptoms associated with fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> call for potassium supplementation and salt poor or salt-free diets, these may be instituted and are compatible with diet requirements for <span class="product-label-link" type="condition" conceptid="75580" conceptname="Chronic ulcerative proctitis">ulcerative proctitis</span>.</p>
<p><span class="Italics">Gastrointestinal</span>:  Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, elevation in serum liver enzyme levels (usually reversible upon discontinuation), <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, perforation of the small and large intestine (particularly in patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>), ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p><span class="Italics">Metabolic</span>: Negative nitrogen balance due to protein catabolism.</p>
<p><span class="Italics">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads, Charcot-like <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>.</p>
<p><span class="Italics">Neurologic/Psychiatric</span>: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually following discontinuation of treatment, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, psychic disorders, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Italics">Ophthalmic</span>: <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, rare instances of <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> associated with periocular injections.</p>
<p><span class="Italics">Other</span>: Abnormal fat deposits, decreased resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, increased or decreased motility and number of spermatozoa, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_F44F845B-75CC-4423-B48E-CC3F5EC5DCAA"></a><a name="section-9"></a><p></p>
<h1>Overdosage</h1>
<p class="First">Treatment of acute overdosage is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_8C451B85-99BC-46E4-B47C-09E79209DE68"></a><a name="section-10"></a><p></p>
<h1>Dosage and Administration</h1>
<p class="First">The usual dose is one applicatorful once or twice daily for two or three weeks, and every second day thereafter, administered rectally.  Directions for use, below and on the carton, describe how to use the aerosol container and applicator. Satisfactory response usually occurs within five to seven days marked by a decrease in symptoms. Symptomatic improvement in <span class="product-label-link" type="condition" conceptid="75580" conceptname="Chronic ulcerative proctitis">ulcerative proctitis</span> should not be used as the sole criterion for evaluating efficacy. Sigmoidoscopy is also recommended to judge dosage adjustment, duration of therapy, and rate of improvement.</p>
<p><span class="Italics">It Should Be Emphasized that Dosage Requirements are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient</span>. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient’s condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D0A87274-1325-4B14-B393-E2549EB9ED4D"></a><a name="section-10.1"></a><p></p>
<h2>Directions For Use</h2>
<p class="First">(1)Shake foam container vigorously for 5-10 seconds before each use. <span class="Bold"><span class="Emphasis">Do not remove container cap during use of the product.</span></span></p>
<p>(2)Hold container upright on a level surface and gently place the tip of the applicator onto the nose of the container cap. CONTAINER MUST BE HELD UPRIGHT TO OBTAIN PROPER FLOW OF MEDICATION.</p>
<p>(3)Pull plunger past the fill line on the applicator barrel.</p>
<p>(4)To fill applicator barrel, press down firmly on cap flanges, hold for 1 – 2 seconds and release.  Pause 5 – 10 seconds to allow foam to expand in applicator barrel. Repeat until foam reaches fill line. Remove applicator from container cap. Allow some foam to remain on the applicator tip.  A burst of air may come out of container with first pump.</p>
<p>(5)Hold applicator firmly by barrel, making sure thumb and middle finger are positioned securely underneath and resting against barrel wings. Place index finger over the plunger. Gently insert tip into anus. Once in place, push plunger to expel foam, then withdraw applicator.</p>
<p><span class="Bold"><span class="Emphasis">CAUTION: Do not insert any part of the aerosol container directly into the anus.  Apply to anus only with enclosed applicator.</span></span></p>
<p>(6)After each use, applicator parts should be pulled apart for thorough cleaning with warm water. The container cap and underlying tip should also be pulled apart and rinsed to help prevent build-up of foam and possible blockage.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_C242B08C-2EAA-4C59-A240-0D8473A5DCB9"></a><a name="section-11"></a><p></p>
<h1>How Supplied</h1>
<p class="First">Cortifoam® is supplied in an aerosol container with a special rectal applicator. Each applicator delivers approximately 900 mg of foam containing approximately 80 mg of hydrocortisone as 90 mg of hydrocortisone acetate. When used correctly, the aerosol container will deliver a minimum of 14 applications.</p>
<p>NDC 0091-0695-2</p>
<p>15 g</p>
<p>Store at controlled room temperature, 20°-25°C (68°-77°F).</p>
<p>DO NOT REFRIGERATE.</p>
<p><span class="Bold"><span class="Emphasis">Rx Only</span></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CORTIFOAM 		
					</strong><br><span class="contentTableReg">hydrocortisone acetate aerosol, foam</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0091-0695</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RECTAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydrocortisone acetate</strong> (hydrocortisone) </td>
<td class="formItem"></td>
<td class="formItem">90 mg  in 900 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>emulsifying wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyoxyethylene-10-stearyl ether</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cetyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>trolamine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isobutane</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propane</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0091-0695-20</td>
<td class="formItem">15 g in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Schwarz Pharma</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7152A68F-1BA9-7555-4FBF-9A69741CD1B4</div>
<div>Set id: 36F623DF-2AE3-4858-9783-C058097951F4</div>
<div>Version: 2</div>
<div>Effective Time: 20070227</div>
</div>
</div> <div class="DistributorName">Schwarz Pharma</div></p>
</body></html>
